1. What Is the Ophthalmic Insert Market?
The Ophthalmic Insert Market encompasses solid and semi-solid ocular drug delivery systems placed on or within the eye to achieve controlled sustained drug release over days, weeks, or months. They provide alternatives to frequent eye drop self-administration for chronic ocular conditions. The market includes lacrisert hydroxypropylcellulose inserts for dry eye, Ozurdex dexamethasone vitreous implants for posterior uveitis and macular oedema, drug-eluting contact lens inserts, periocular subconjunctival drug depot implants, and bioerodible and non-erodible sustained-release ophthalmic inserts. These devices are placed by ophthalmologists in the lower conjunctival sac, subconjunctival space, or vitreous cavity to deliver sustained therapeutic drug concentrations over extended periods, reducing the high drop burden of chronic ophthalmic therapy. Market scope covers ophthalmic drug insert and implant delivery systems designed for sustained drug release at the anterior or posterior segment. It excludes conventional eye drop solution and suspension formulations, ophthalmic ointments and gels, and intravitreal port delivery systems for anti-VEGF injection.
2. Ophthalmic Insert Market Size & Forecast
3. Emerging Technologies
- Bimatoprost intracameral sustained-release implant technology is advancing bioerodible polymer matrices loaded with prostaglandin analogue that are injected into the anterior chamber angle during office procedure to release bimatoprost for 4 to 6 months. Growing.
- Subconjunctival microparticle depot technology is advancing bioerodible microsphere formulations injected subconjunctivally to achieve weeks of sustained drug release in the anterior segment from office-based injection procedures, targeting glaucoma. Growing industry adoption of this technology is motivating development.
- Punctal plug drug delivery insert technology is advancing silicone punctal plug designs with integrated drug matrices releasing lacrimal pathway drug concentrations of cyclosporine, latanoprost, and dexamethasone into the tear film without patient interaction. Growing.
- Supra-choroidal drug delivery insert technology is advancing bioerodible disc implants placed in the suprachoroidal space to achieve targeted posterior segment drug delivery with reduced systemic exposure and anterior segment side effects compared with intravitreal. Growing industry adoption of this technology is motivating development.
Such innovations are driving change across adjacent industries too. Discover more in our Ophthalmic Suspension Market.
4. Key Market Opportunity
A major opportunity in the Ophthalmic Insert Market is the commercial launch and adoption of sustained-release bimatoprost intracameral implant systems that address glaucoma medication non-adherence by eliminating the daily drop compliance variable for IOP control in office-managed patients. A significant proportion of glaucoma patients on topical IOP-lowering therapy demonstrate measurable non-adherence that results in uncontrolled IOP and glaucoma progression, yet clinical visits cannot distinguish adherent from non-adherent patients due to white-coat compliance behaviour at appointments. Intracameral bimatoprost implants that provide 4 to 6 months of controlled prostaglandin delivery from a single in-office procedure eliminate the adherence variable, providing reliably consistent IOP control without reliance on patient self-administration behaviour. Ophthalmic insert manufacturers that achieve regulatory approval for intracameral sustained-release prostaglandin implants with demonstrable IOP control equivalent to adherent daily drop therapy and office-based procedure economics competitive with alternative interventional glaucoma procedures are positioned for significant market uptake.
5. Top Companies in the Ophthalmic Insert Market
The following organisations hold leading positions in the Ophthalmic Insert Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- AbbVie (Ozurdex)
- Alimera Sciences (Iluvien)
- Glaukos
- Clearside Biomedical
- Ocular Therapeutix
- pSivida
- EyePoint Pharmaceuticals
- InVivo Therapeutics
- Eyenovia
- Santen Pharmaceutical
6. Market Segmentation
The Ophthalmic Insert Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Insert Type | Bioerodible Insert Biodegradable Polymer Insert Collagen Shield Insert Non-Erodible Insert ELVAX Insert Non-Biodegradable Matrix Drug-Eluting Contact Lens Soft Contact Lens Drug Insert Bandage Lens Drug Eluting Intravitreal Implant Ozurdex Dexamethasone Implant Iluvien Fluocinolone Implant Subconjunctival Depot Microparticle Depot Inject Periocular Insert Punctal Plug Drug Insert Conjunctival Drug Insert |
| By Drug Payload | Corticosteroid Dexamethasone Insert Fluocinolone Insert Dry Eye Agent Hydroxypropylcellulose Insert Cyclosporine Insert Glaucoma Agent Bimatoprost Insert Travoprost Punctal Plug Antibiotic Antibiotic Eluting Insert Anti-Inflammatory NSAID Eluting Insert |
| By Indication | Posterior Uveitis Non-Infectious Posterior Uveitis Diabetic Macular Oedema DME Steroid Implant Dry Eye Disease Severe Aqueous Deficiency Dry Eye Glaucoma Bimatoprost Ring Post-Operative Post-Cataract Steroid Insert |
| By End User | Ophthalmologists Retina Specialists Glaucoma Specialists Hospitals Retina Centre Ambulatory Surgery Centres Intravitreal Procedure Centres |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Ophthalmic Insert Market trajectory over the forecast period:
Ozurdex Biodegradable Dexamethasone Vitreous Implant Is Establishing Intravitreal Steroid Insert as the Standard for Non-Infectious Posterior Uveitis Management.Retina specialists managing non-infectious posterior. Intermediate uveitis are increasing Ozurdex intravitreal implant use as the biodegradable corticosteroid implant provides up to six months of controlled dexamethasone release, reducing reliance on frequent systemic immunosuppressive therapy and intravitreal injection visits. AbbVie continued commercial development and expanded approval pursuit of Ozurdex in additional posterior uveitis and diabetic macular oedema indications in 2024, growing retina specialist awareness and prescription volume across vitreoretinal practices managing inflammatory. These practices include vascular posterior segment conditions.
Iluvien Non-Erodible Fluocinolone Insert Is Providing Three-Year Sustained Corticosteroid Delivery for Diabetic Macular Oedema in Pseudophakic Eyes.Retina specialists managing pseudophakic diabetic macular oedema patients with chronic recurrent inflammation who are steroid responders are using Iluvien fluocinolone acetonide intravitreal implant to achieve three years of controlled corticosteroid delivery. From a single intravitreal injection, reducing the injection visit burden compared with anti-VEGF monthly injection regimens. Alimera Sciences continued commercial expansion of Iluvien intravitreal fluocinolone implant across United States and European markets in 2024. Retina specialists increasing adoption for pseudophakic DME patients where corticosteroid mechanism targets the inflammation component of diabetic macular oedema.
Drug-Eluting Contact Lens Insert Technology Is Advancing Towards Preservative-Free Drug Delivery Without Daily Eye Drop Application for Glaucoma and Dry Eye.Ophthalmologists and contact lens specialists evaluating drug-eluting contact lens technologies are assessing latanoprost-eluting and cyclosporine-eluting contact lens systems as alternatives to daily eye drop installation for patients with glaucoma. Dry eye who prefer contact lens-based drug delivery. Eyenovia advanced clinical development of the Optejet microdose array dispenser and drug-eluting contact lens platform for glaucoma drug delivery in 2024, and research groups at multiple institutions published updated in vitro. In vivo data on bimatoprost and latanoprost-eluting contact lens delivery systems for IOP reduction.
For related market intelligence, see the Ophthalmic Solution Market.
8. Segmental Analysis
By insert type, intravitreal implants dominated the Ophthalmic Insert Market in 2025, driven by the established adoption of Ozurdex and Iluvien steroid implants for posterior uveitis and diabetic macular oedema at retina specialist practices globally. Retina specialists continue specifying intravitreal corticosteroid implants for posterior segment inflammatory conditions as biodegradable and non-erodible steroid insert technology provides months of controlled drug release with fewer office injection visits than conventional intravitreal injection regimens. Drug-eluting contact lenses are the fastest-growing insert type, driven by growing clinical development pipeline activity for glaucoma, dry eye, and post-operative drug-eluting contact lens platforms and increasing ophthalmologist awareness of patient-friendly lens-based drug delivery. Ophthalmologists are increasing evaluation of drug-eluting contact lens technology as clinical evidence accumulates for effective drug delivery of latanoprost and cyclosporine through contact lens matrices with patient compliance advantages over daily eye drop regimens.
By indication, posterior uveitis dominated the Ophthalmic Insert Market in 2025, driven by the established Ozurdex indication for non-infectious posterior and intermediate uveitis and retina specialist preference for intravitreal steroid insert therapy. Retina specialists managing non-infectious posterior uveitis continue specifying Ozurdex intravitreal dexamethasone implant as their preferred steroid therapy as the six-month controlled release duration reduces injection frequency versus intravitreal triamcinolone repeat dosing. Glaucoma management is the fastest-growing indication, driven by advancing clinical development of bimatoprost intracameral implant and drug-eluting contact lens systems as maintained-release alternatives to daily prostaglandin analogue drop compliance. Glaucoma specialists are increasing clinical and commercial interest in maintained-release prostaglandin implant technology as adherence-independent IOP control addresses the primary compliance failure mode in chronic open-angle glaucoma management.
9. Regional Analysis
Regional demand patterns across the Ophthalmic Insert Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Ophthalmic Insert Market in 2025, with a market share of 42.0%. The region's leadership reflects the high retina specialist concentration in the United States using Ozurdex and Iluvien intravitreal inserts for posterior uveitis and DME, comprehensive insurance coverage for approved intravitreal implants, and strong clinical trial activity for advanced ophthalmic insert technologies at North American academic eye centres. The large United States retina specialist and glaucoma specialist community generates consistent Ozurdex and Iluvien insert procurement demand for posterior uveitis and diabetic macular oedema management at retina practices and vitreoretinal surgery centres. Growing United States glaucoma specialist interest in extended-release prostaglandin implant technologies and drug-eluting contact lens systems for non-adherent glaucoma patients is creating early clinical adoption activity that will drive insert market growth through the forecast period.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 12.40% during the forecast period. Growing retina specialist density, increasing posterior uveitis and diabetic macular oedema treatment access, and expanding ophthalmology programme investment in advanced ophthalmic drug delivery technology in Japan, South Korea, China, Australia, and India are creating demand for intravitreal implants and ophthalmic insert technology. Growing diabetic retinopathy and diabetic macular oedema treatment volumes in the large type 2 diabetes populations of China, India, Japan, and Southeast Asia are creating demand for intravitreal corticosteroid insert therapy as an alternative or adjunctive option to anti-VEGF injection for pseudophakic DME patients. Growing ophthalmology research and clinical trial activity at academic eye institutes in Japan, South Korea, and China is advancing local regulatory submissions for ophthalmic insert technologies and creating awareness of extended drug delivery among Asia Pacific retina and glaucoma specialists.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Ophthalmic Insert Market was valued at USD 1.81 Bn in 2025 and is projected to reach USD 4.10 Bn by 2034, growing at a CAGR of 9.50% over the 2026–2034 forecast period.
The Ophthalmic Insert Market is projected to grow at a CAGR of 9.50% from 2026 to 2034.
North America dominated the Ophthalmic Insert Market in 2025, with a market share of 42.0%.
The leading companies in the Ophthalmic Insert Market include AbbVie (Ozurdex), Alimera Sciences (Iluvien), Glaukos, Clearside Biomedical, Ocular Therapeutix, pSivida, EyePoint Pharmaceuticals, InVivo Therapeutics, Eyenovia, Santen Pharmaceutical.
Ozurdex biodegradable dexamethasone vitreous implant is establishing intravitreal steroid insert as the standard for non-infectious posterior uveitis management.
By insert type, intravitreal implants dominated the Ophthalmic Insert Market in 2025, driven by the established adoption of Ozurdex and Iluvien steroid implants for posterior uveitis and diabetic macular oedema at retina specialist practices globally.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.